New drugs: acamprosate calcium and solifenacin succinate.
Hussar
Daniel A
DA
Philadelphia College of Pharmacy, University of the Sciences, PA, USA.
D000077443:Acamprosate; D000328:Adult; D000437:Alcoholism / Q000188:drug therapy / Q000401:mortality / Q000503:physiopathology; D018680:Cholinergic Antagonists / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D004348:Drug Labeling; D005260:Female; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced; D008875:Middle Aged; D011247:Pregnancy / Q000187:drug effects; D011812:Quinuclidines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000069464:Solifenacin Succinate; D013608:Tablets, Enteric-Coated; D013654:Taurine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*; D044005:Tetrahydroisoquinolines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D014549:Urinary Incontinence / Q000188:drug therapy / Q000503:physiopathology
D018680:Cholinergic Antagonists; D011812:Quinuclidines; D013608:Tablets, Enteric-Coated; D044005:Tetrahydroisoquinolines; D013654:Taurine; D000069464:Solifenacin Succinate; D000077443:Acamprosate